-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-125 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-125 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-125 in Retinitis Pigmentosa (Retinitis) Drug Details: 4D-125 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-2990 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-2990 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-2990 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KYV-101 in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KYV-101 in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KYV-101 in Systemic Sclerosis (Scleroderma) Drug Details: KYV-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATSN-101 in Leber Congenital Amaurosis (LCA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATSN-101 in Leber Congenital Amaurosis (LCA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATSN-101 in Leber Congenital Amaurosis (LCA) Drug Details: ATSN-101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-150 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Diabetic Macular Edema Drug Details: 4D-150 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mydicar in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mydicar in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mydicar in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ixoberogene Soroparvovec in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ixoberogene Soroparvovec in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ixoberogene Soroparvovec in Wet (Neovascular / Exudative)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lanacogene Vosiparvovec in Hemophilia B (Factor IX Deficiency)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mydicar in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mydicar in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mydicar in Diastolic Heart Failure (HFpEF) Drug Details: Mydicar is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTA-101 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTA-101 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTA-101 in Diffuse Large B-Cell Lymphoma Drug Details: CTA-101 is...